BR112022007680A2 - Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos - Google Patents

Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos

Info

Publication number
BR112022007680A2
BR112022007680A2 BR112022007680A BR112022007680A BR112022007680A2 BR 112022007680 A2 BR112022007680 A2 BR 112022007680A2 BR 112022007680 A BR112022007680 A BR 112022007680A BR 112022007680 A BR112022007680 A BR 112022007680A BR 112022007680 A2 BR112022007680 A2 BR 112022007680A2
Authority
BR
Brazil
Prior art keywords
quinazolin
heteroaryl
pharmaceutical compositions
amine derivatives
present
Prior art date
Application number
BR112022007680A
Other languages
English (en)
Inventor
H Keylor Mitchell
J Ardolino Michael
W Chau Ryan
H Fuller Peter
Gulati Anmol
Elizabeth Johnson Rebecca
D Kattar Solomon
A Margrey Kaila
J Morriello Gregori
F Neelamkavil Santhosh
Yan Xin
C Yu Elsie
Carmela Zarate Saez Cayetana
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112022007680A2 publication Critical patent/BR112022007680A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE N-(HETEROARIL)QUINAZOLIN-2-AMINA COMO INIBIDORES DE LRRK2, COMPOSIÇÕES FARMACÊUTICAS, E USOS DOS MESMOS. A presente invenção é direcionada a certos derivados de N-(heteroaril)quinazolin-2-amina substituídos de Fórmula (I):e sais farmaceuticamente aceitáveis dos mesmo, em que J, R3, e R4, são como definidos na presente invenção, os quais são inibidores potentes de quinase LRRK2 e podem ser úteis no tratamento ou prevenção de doenças nas quais a quinase LRRK2 está envolvida, tais como Doença de Parkinson e outras doenças e distúrbios descritos na presente invenção. A presente invenção também é direcionada a composições farmacêuticas compreendendo esses compostos e o uso desses compostos e composições na prevenção ou tratamento de doenças, tais como a doença de Parkinson, nas quais a quinase LRRK-2 está envolvida.
BR112022007680A 2019-10-25 2020-10-20 Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos BR112022007680A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926033P 2019-10-25 2019-10-25
PCT/US2020/056401 WO2021080929A1 (en) 2019-10-25 2020-10-20 N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Publications (1)

Publication Number Publication Date
BR112022007680A2 true BR112022007680A2 (pt) 2022-08-09

Family

ID=75620799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007680A BR112022007680A2 (pt) 2019-10-25 2020-10-20 Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230023066A1 (pt)
EP (1) EP4048261A4 (pt)
JP (1) JP2023502857A (pt)
KR (1) KR20220088744A (pt)
CN (1) CN115243687A (pt)
AU (1) AU2020371556A1 (pt)
BR (1) BR112022007680A2 (pt)
CA (1) CA3154247A1 (pt)
MX (1) MX2022004878A (pt)
WO (1) WO2021080929A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
EP2150255A4 (en) * 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
BR112014002675A2 (pt) * 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
WO2014134774A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AU2014331794C1 (en) * 2013-10-10 2019-09-12 Araxes Pharma Llc Inhibitors of KRAS G12C
US11174248B2 (en) * 2017-10-11 2021-11-16 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

Also Published As

Publication number Publication date
EP4048261A1 (en) 2022-08-31
US20230023066A1 (en) 2023-01-26
AU2020371556A1 (en) 2022-05-05
CA3154247A1 (en) 2021-04-29
KR20220088744A (ko) 2022-06-28
WO2021080929A1 (en) 2021-04-29
JP2023502857A (ja) 2023-01-26
MX2022004878A (es) 2022-05-13
CN115243687A (zh) 2022-10-25
EP4048261A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
BR112021026395A2 (pt) Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112018075663A2 (pt) compostos e composições para a inibição da atividade de shp2
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112018015289A2 (pt) compostos de benzopirazol e análogos dos mesmos
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BRPI0507065A (pt) derivados de quinolina e seu uso como inibidores micobacterianos
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
PL378136A1 (pl) Pirymidyny i triazyny hamujące replikacją wirusa HIV
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112022021514A2 (pt) [1,3]diazino[5,4-d]pirimidinas como inibidores de her2
BR112022000431A2 (pt) Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)